GlobeNewswire Press

  1. Jounce Therapeutics Initiates Phase 2 EMERGE Study Of Vopratelimab In Combination With Ipilimumab In Patients With Non-Small Cell Lung Cancer Or Urothelial Cancer 6/18/2019

    Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has initiated dosing in the Phase 2 EMERGE clinical trial of its lead product candidate, vopratelimab, in combination with ipilimumab in patients with non-small cell lung cancer (NSCLC) or urothelial cancer who have progressed on or after PD-1/PD-L1 inhibitor therapies.

  2. Sanofi And Google To Develop New Healthcare Innovation Lab 6/18/2019

    Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies.

  3. Abeona Therapeutics Receives FDA Fast Track Designation For ABO-202 AAV9 Gene Therapy In CLN1 Disease 6/18/2019

    Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its ABO-202 program.

  4. Protalix BioTherapeutics Completes Enrollment In The Phase III BRIGHT Clinical Trial Of Pegunigalsidase Alfa (PRX 102) For The Treatment Of Fabry Disease 6/17/2019

    Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment in the phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX‑102, for the treatment of Fabry disease, via intravenous (IV) infusions of 2 mg/kg administered every 4 weeks.

  5. Aptinyx Reports Positive Top-Line Data From Phase 2 Study Of NYX-2925 In Patients With Fibromyalgia, Demonstrating Significant Effects On Both Biomarkers And Patient-Reported Pain 6/10/2019

    Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive top-line results from a 23-patient, single-blind, sequential design Phase 2 study of its novel NMDA receptor modulator, NYX-2925, in patients with fibromyalgia.

  6. ContraVir Pharmaceuticals Sets The Stage For CRV431 Development In NASH With Positive Results From Second Model Of Liver Fibrosis 6/6/2019

    ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from a preclinical study where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of fibrosis in a second animal model of liver fibrosis.

  7. Centrexion Therapeutics Announces Completion Of Patient Enrollment In Pivotal Clinical Trial Of Repeat Doses Of CNTX-4975 In Patients With Moderate To Severe Osteoarthritis Knee Pain 6/5/2019

    Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced completion of patient enrollment in its second pivotal trial, VICTORY-2, a randomized, double-blind, placebo-controlled, repeat injection at 6 months, 52-week study to evaluate the efficacy and safety of intra-articular (IA) injections of CNTX-4975 in 332 participants with chronic moderate-to-severe knee osteoarthritis (OA) pain.

  8. Forty Seven, Inc. Announces Updated Initial Data From Phase 1b Clinical Trial Of 5F9 In Patients With Myelodysplastic Syndrome And Acute Myeloid Leukemia 6/3/2019

    Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced updated initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

  9. BrainStorm Announces Second Clinical Site To Enroll Patients In Its Progressive MS Phase 2 Study 5/30/2019

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that the Stanford University School of Medicine will serve as the second contracted clinical study site for the Company’s Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive Multiple Sclerosis (MS) (NCT03799718).

  10. Reata Announces First Patient Enrolled In Phase 3 FALCON Trial Of Bardoxolone Methyl For The Treatment Of Autosomal Dominant Polycystic Kidney Disease 5/30/2019

    Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the Phase 3 FALCON trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD).